MétaCan
Menu
← Back to cohort
Record W4281767182 · doi:10.26685/urncst.342

The Diverse Roles of Monoclonal Antibodies in Cancer Immunotherapy and Their Relative Effectiveness: A Literature Review

2022· review· en· W4281767182 on OpenAlexaff
Rowan Ives, Kyobin Hwang

Bibliographic record

VenueUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · 2022
Typereview
Languageen
FieldMedicine
TopicMonoclonal and Polyclonal Antibodies Research
Canadian institutionsMcMaster University
Fundersnot available
KeywordsImmune systemMonoclonal antibodyImmunotherapyCancer immunotherapyCancerImmunologyAntibodyCancer researchMedicineAntigenCancer cellBiologyInternal medicine

Abstract

fetched live from OpenAlex

Introduction: In modern oncology, immunotherapy has emerged as a promising treatment modality for numerous cancers. At the forefront of personalized medicine, immunotherapy utilizes components of a patient's immune system to selectively target cancer cells. Numerous immunotherapy drugs have been developed thus far, including monoclonal antibodies (mAbs). mAbs are genetically-identical protein antibodies created in the laboratory through recombinant DNA technology. They are capable of recognizing molecules that are uniquely present on the surface of cancer cells, such as tumour-specific antigens and/or receptors. This narrative review explores the various uses of mAbs in the treatment of cancer. Methods: A narrative literature review was conducted to analyse and synthesize current and prior research surrounding the various uses of mAbs in the context of cancer treatment. Specific examples and potential shortfalls of various treatment methods were also analysed. Results: mAbs can be used in several distinct ways to target cancerous cells. In their native immunoglobulin G form, mAbs direct immune cells to tumours and induce cytotoxicity via initiating biochemical cascades, leading to effects such as phagocytosis, opsonisation, activation of immune cells, degranulation, and cytokine release, among others. mAbs may also be conjugated with radionuclides, or traditional chemotherapeutic agents for targeted drug delivery, or used to target the immune system via conjugation to cytokines, or other mAbs which directly interact with immune cells for targeted recruitment. mAbs targeting immune checkpoints can also be used to enhance cancer-related immune responses. However, mAbs are not perfect, and are thus prone to a slew of limitations which are still being addressed. Discussion: mAbs are highly useful, primarily as a result of their specific molecular recognition abilities. This property underlies all uses in cancer immunotherapy and can further be exploited in the development of new immunotherapy technologies and methodologies, along with the elucidation of novel antigens and targets in cancers, to further improve the field and address limitations. Conclusions: This literature review aims to synthesize data pertaining to the various potential uses of mAbs in cancer treatment. This approach will provide more insight into the current state of immunotherapeutics, and where additional research must be conducted.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.007
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.009
Threshold uncertainty score0.014

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.007
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0090.008
Science and technology studies0.0000.001
Scholarly communication0.0020.002
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0040.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.104
GPT teacher head0.489
Teacher spread0.386 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueUndergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal→Same topicMonoclonal and Polyclonal Antibodies Research→French-language works237,207→